Zydus Lifesciences has appealed a Delhi High Court order. The order restricts it from producing a biosimilar of E.R. Squibb's Nivolumab. Squibb alleges patent infringement of its cancer drug Opdyta. Zydus denies infringement, stating its product ZRC-3276 is biosimilar but doesn't violate patents. Zydus argues the process is known and its subsidiary filed a post-grant opposition.